pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-144 |
Genomic Coordinates | chr17: 28861533 - 28861618 |
Description | Homo sapiens miR-144 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-144-3p | |||||||||||||||||||||
Sequence | 52| UACAGUAUAGAUGAUGUACU |71 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | TMBIM6 | ||||||||||||||||||||
Synonyms | BAXI1, BI-1, TEGT | ||||||||||||||||||||
Description | transmembrane BAX inhibitor motif containing 6 | ||||||||||||||||||||
Transcript | NM_001098576 | ||||||||||||||||||||
Other Transcripts | NM_003217 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on TMBIM6 | |||||||||||||||||||||
3'UTR of TMBIM6 (miRNA target sites are highlighted) |
>TMBIM6|NM_001098576|3'UTR 1 AGTGACCATCCAGCCTTTCCCAATTAGACTTCCTCTCCTTCCACCCCTCATTTCCTTTTTGCACACATTACAGGTGGTGT 81 GTTCTGTGATAATGAAAAGCATCAGAAAAGCTTTTGTACTTTGTGGTTTCCTCTATTTTGAATTTTTTGATCAAAAAACT 161 GATTAGCAGAATATAGTTTGGAGTTTGGCTTCATCTTCCTGGGGTTCCCCTCACTCCCTTTTTTGTCAACCCCATCTGTA 241 GCCTCTTCCTCTACTCAGGCAGTCGACCCGCCACGATGAGAAGTGGGACCAGCAGAGGGCGCCAACTTCAGGAGTCCGCT 321 TTCCCACCAGGCTTCATTCACCCAGTGGACCTGAACTGTTTGGTAGAGCCACCCGGCCCTTCCTTCCTCATTGTTGTTTG 401 GTATGCGCACAGTTCCTGTGGGACTGGGCCGTGAGTTTTCCATTGGAAAGAAGTTCAGTGGTCCCATTGTTAACTCAGCC 481 TCAAATCTCAACTGTCAGGCCCTACAAAGAAAATGGAGAGCCTCTTCTGGTGGATGCTTTGCTCCCTCTGAGCTGCCCAT 561 GCTGGTCTGGCAAACACACCTTTCTGCTTTGCCTTCACAAAAGTAATGTGTTCCCTTTCCCACCCCTTGCCTGACCCTCA 641 GGGAGTCAGCCTGCTTCCATCCATGGGTGGGAAGACTTCAGCACAAAGGAAAGACTAATTCTTGTCAGGCATTTTTGAAA 721 AGGCTGATTATGTGTATCAAGGTACAGCATCGTAGGGTTCCCCTAAACTTGCCCTGTTTTTGTTTTTTTAGTTTGTTATC 801 CCCTTACTGAGCGGCCTCTACTAGGTGGCTGTGATTAAATGTCCCAAGCAAGGATAGGGAAGGGGAATGGTTGAGCCTCT 881 GGAGATCATTGTAACCAATCCTGCCAGACCTGTTTGGGGCAGTGGGGAGCAAACCTAGATAAGGACCTGTTTGGGGCAGC 961 AGGGAGCAAAATCTCCTTTAACAACCAAGCAGTTCCTCATTCACATCAACAGAGCGAGGCTGTGATAACTTAGGAGGCAG 1041 CAATCCTAATAGTCCTTCAGTGCATTTTAGTCTGTCTCCAACTGGACACCAGTAGGTAGTGTCAAGCCAGAGATTCGGGG 1121 CAGTAGATAAATGTTCATTTTACTGATGCACTTTAGTTTTTGGTCTGTTACCTGTTTTCCAGAAATTTGTGGCCTTTTAG 1201 GCGGGAGTTAGGCGACCAAACCAGTGAGAGCCCCAATCCCTGCAGTTTTGTGGCTTCAAGTGTGGGTGGACAGTCCTAAT 1281 GGGGATCTCCAGCTCCTTCCTGTGGGCTGCCACAGACAGCTACCCCCAGAAGGGTCAATGTTGGGAGTGGTTGTGGCTCT 1361 GAGCTGCTCTACAGAGCTTCAGTGTGAGAGGATCGAGCCATTGAAAGCTCATTACCAGTAGGACATAATTTTTGGCTCTC 1441 CCTATTCACAACCAGTGCACAGTTTGACACAGTGGCCTCAGGTTCACAGTGCACCATGTCACTGTGCTATCCTACGAAAT 1521 CATTTGTTTCTAAGTTGTGTTTATTCCTGGAGTGACATGCCACCCCGAATGGCTCACTTTCACTGAGGATGCTGTCCTCT 1601 GATTTAGCTGCTGCCTCCAGCCTCTGGCTTGAGAACTTACTAAAGGCACTTCCTTCCTGTTAAACCCCTGTTAACTCTCC 1681 ATAAATTTGGTGATTCTCTGCTAGGCCTAAGATTTTGAGTTAACATCTCTTGAAGCCAAACTCCACCTTCTGTGCTTTTT 1761 GCTTGGGATAATGGAGTTTTTCTTTAGAAACAGTGCCAAGAATGACAAGATATTAAAAAAAAAAAAGAAAGAAAAAAAAA 1841 AAAACACCTACTTTTAAAGAAAATACCTAACAGATTTTTAATATAGTTATCTCTACCACTTTCTTTTCTAGTTTCTTGAT 1921 TTTCAGCTCAGGCTGCATTCTAACTCATACTGTGAAGACAAAGGTGTTTTTGATTCAGAAATATATGAAATCTGCATAGT 2001 CTTAATTTGTAAAAAATAAAGAAAATTCCTTAACCTTTA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Disease | 7009.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065669. RNA binding protein: AGO1. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HCT116 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in ERX177600. RNA binding protein: AGO2. Condition:p53_V_Ago_CLIP_2_2
PAR-CLIP data was present in ERX177602. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_2_4
PAR-CLIP data was present in ERX177604. RNA binding protein: AGO2. Condition:p53_V_AGO_CLIP_2_6
PAR-CLIP data was present in ERX177610. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_2_12
PAR-CLIP data was present in ERX177612. RNA binding protein: AGO2. Condition:p53_V_AGO_CLIP_3_2
PAR-CLIP data was present in ERX177620. RNA binding protein: AGO2. Condition:p53_V_AGO_CLIP_3_10
PAR-CLIP data was present in ERX177624. RNA binding protein: AGO2. Condition:p53_V_AGO_CLIP_4_2
PAR-CLIP data was present in ERX177626. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_4_4
PAR-CLIP data was present in ERX177634. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_4_12
PAR-CLIP data was present in ERX177614. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_3_4
PAR-CLIP data was present in ERX177616. RNA binding protein: AGO2. Condition:p53_V_AGO_CLIP_3_6
... - Krell J; Stebbing J; Carissimi C; Dabrowska et al., 2016, Genome research. |
Article |
- Krell J; Stebbing J; Carissimi C; Dabrowska et al. - Genome research, 2016
DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2's association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.
LinkOut: [PMID: 26701625]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Prostate Tissue |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760597. RNA binding protein: AGO2. Condition:AGO-CLIP-LNCaP_C
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000423828.1 | 3UTR | AUUUUCAGCUCAGGCUGCAUUCUAACUCAUACUGUGAAGA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1065669 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_8 |
Location of target site | ENST00000423828.1 | 3UTR | UUUUCAGCUCAGGCUGCAUUCUAACUCAUACUGUGAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
204 hsa-miR-144-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT003058 | PLAG1 | PLAG1 zinc finger | 2 | 1 | ||||||||
MIRT005523 | FGG | fibrinogen gamma chain | 2 | 1 | ||||||||
MIRT005529 | FGA | fibrinogen alpha chain | 2 | 1 | ||||||||
MIRT005530 | FGB | fibrinogen beta chain | 2 | 1 | ||||||||
MIRT005869 | NOTCH1 | notch 1 | 4 | 2 | ||||||||
MIRT006114 | TGFB1 | transforming growth factor beta 1 | 4 | 1 | ||||||||
MIRT006872 | MTOR | mechanistic target of rapamycin kinase | 7 | 3 | ||||||||
MIRT007190 | PTEN | phosphatase and tensin homolog | 3 | 1 | ||||||||
MIRT007310 | NFE2L2 | nuclear factor, erythroid 2 like 2 | 1 | 1 | ||||||||
MIRT053494 | ZFX | zinc finger protein, X-linked | 6 | 5 | ||||||||
MIRT054058 | CFTR | cystic fibrosis transmembrane conductance regulator | 2 | 1 | ||||||||
MIRT054851 | TTN | titin | 3 | 1 | ||||||||
MIRT057677 | LCOR | ligand dependent nuclear receptor corepressor | 2 | 8 | ||||||||
MIRT065418 | TMBIM6 | transmembrane BAX inhibitor motif containing 6 | 2 | 4 | ||||||||
MIRT066720 | CCT2 | chaperonin containing TCP1 subunit 2 | 2 | 6 | ||||||||
MIRT066784 | ARID1A | AT-rich interaction domain 1A | 2 | 2 | ||||||||
MIRT067387 | TMTC3 | transmembrane and tetratricopeptide repeat containing 3 | 2 | 4 | ||||||||
MIRT068846 | FNDC3A | fibronectin type III domain containing 3A | 2 | 2 | ||||||||
MIRT069645 | BCL2L2-PABPN1 | BCL2L2-PABPN1 readthrough | 2 | 2 | ||||||||
MIRT069657 | PABPN1 | poly(A) binding protein nuclear 1 | 2 | 2 | ||||||||
MIRT071717 | CCNK | cyclin K | 2 | 2 | ||||||||
MIRT073564 | NR2F2 | nuclear receptor subfamily 2 group F member 2 | 2 | 4 | ||||||||
MIRT080720 | ZCCHC2 | zinc finger CCHC-type containing 2 | 2 | 4 | ||||||||
MIRT090617 | PLS1 | plastin 1 | 2 | 2 | ||||||||
MIRT097062 | TNPO1 | transportin 1 | 2 | 4 | ||||||||
MIRT102618 | UBN2 | ubinuclein 2 | 2 | 4 | ||||||||
MIRT118769 | FAM217B | family with sequence similarity 217 member B | 2 | 6 | ||||||||
MIRT147282 | KPNA2 | karyopherin subunit alpha 2 | 2 | 10 | ||||||||
MIRT159513 | DYNC2LI1 | dynein cytoplasmic 2 light intermediate chain 1 | 2 | 2 | ||||||||
MIRT196438 | TAOK1 | TAO kinase 1 | 2 | 2 | ||||||||
MIRT211238 | FGF2 | fibroblast growth factor 2 | 2 | 2 | ||||||||
MIRT220422 | MKLN1 | muskelin 1 | 2 | 2 | ||||||||
MIRT223668 | FZD6 | frizzled class receptor 6 | 2 | 6 | ||||||||
MIRT223805 | OXR1 | oxidation resistance 1 | 2 | 2 | ||||||||
MIRT238585 | NLN | neurolysin | 2 | 2 | ||||||||
MIRT238652 | JMY | junction mediating and regulatory protein, p53 cofactor | 2 | 2 | ||||||||
MIRT247188 | BTG2 | BTG anti-proliferation factor 2 | 2 | 6 | ||||||||
MIRT249185 | AKIRIN1 | akirin 1 | 2 | 8 | ||||||||
MIRT252653 | LSM14A | LSM14A, mRNA processing body assembly factor | 2 | 4 | ||||||||
MIRT305624 | MBNL1 | muscleblind like splicing regulator 1 | 2 | 2 | ||||||||
MIRT315671 | NUS1 | NUS1 dehydrodolichyl diphosphate synthase subunit | 2 | 6 | ||||||||
MIRT366555 | EIF2S3 | eukaryotic translation initiation factor 2 subunit gamma | 2 | 2 | ||||||||
MIRT403294 | ZNF207 | zinc finger protein 207 | 2 | 2 | ||||||||
MIRT405966 | CHAC1 | ChaC glutathione specific gamma-glutamylcyclotransferase 1 | 2 | 2 | ||||||||
MIRT437437 | EZH2 | enhancer of zeste 2 polycomb repressive complex 2 subunit | 5 | 1 | ||||||||
MIRT438343 | MET | MET proto-oncogene, receptor tyrosine kinase | 5 | 1 | ||||||||
MIRT444395 | ZNF480 | zinc finger protein 480 | 2 | 2 | ||||||||
MIRT445255 | SEMA5A | semaphorin 5A | 2 | 2 | ||||||||
MIRT445309 | MLANA | melan-A | 2 | 2 | ||||||||
MIRT449020 | ANKRD12 | ankyrin repeat domain 12 | 2 | 2 | ||||||||
MIRT452136 | NDUFC2-KCTD14 | NDUFC2-KCTD14 readthrough | 2 | 2 | ||||||||
MIRT459438 | PPIC | peptidylprolyl isomerase C | 2 | 2 | ||||||||
MIRT460471 | MMS22L | MMS22 like, DNA repair protein | 2 | 2 | ||||||||
MIRT461294 | COX10 | COX10, heme A:farnesyltransferase cytochrome c oxidase assembly factor | 2 | 2 | ||||||||
MIRT462948 | ZNF800 | zinc finger protein 800 | 2 | 12 | ||||||||
MIRT463489 | ZC3H11A | zinc finger CCCH-type containing 11A | 2 | 12 | ||||||||
MIRT463846 | WRN | Werner syndrome RecQ like helicase | 2 | 2 | ||||||||
MIRT466183 | TMED5 | transmembrane p24 trafficking protein 5 | 2 | 4 | ||||||||
MIRT466882 | STX16 | syntaxin 16 | 2 | 2 | ||||||||
MIRT468156 | SGPL1 | sphingosine-1-phosphate lyase 1 | 2 | 2 | ||||||||
MIRT468259 | SFXN4 | sideroflexin 4 | 2 | 2 | ||||||||
MIRT469660 | RAC1 | Rac family small GTPase 1 | 2 | 10 | ||||||||
MIRT470040 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 2 | 2 | ||||||||
MIRT470552 | COASY | Coenzyme A synthase | 2 | 2 | ||||||||
MIRT472208 | NGFRAP1 | brain expressed X-linked 3 | 2 | 4 | ||||||||
MIRT472555 | NACC1 | nucleus accumbens associated 1 | 2 | 4 | ||||||||
MIRT473462 | MCL1 | MCL1, BCL2 family apoptosis regulator | 2 | 2 | ||||||||
MIRT473925 | LYSMD3 | LysM domain containing 3 | 2 | 4 | ||||||||
MIRT474068 | LMNB2 | lamin B2 | 2 | 2 | ||||||||
MIRT475079 | ITSN2 | intersectin 2 | 2 | 4 | ||||||||
MIRT475286 | TOR1AIP2 | torsin 1A interacting protein 2 | 2 | 2 | ||||||||
MIRT475570 | HNRNPF | heterogeneous nuclear ribonucleoprotein F | 2 | 2 | ||||||||
MIRT477516 | ELL2 | elongation factor for RNA polymerase II 2 | 2 | 2 | ||||||||
MIRT478464 | DAB2 | DAB2, clathrin adaptor protein | 2 | 2 | ||||||||
MIRT478920 | CPS1 | carbamoyl-phosphate synthase 1 | 2 | 2 | ||||||||
MIRT479338 | CERK | ceramide kinase | 2 | 2 | ||||||||
MIRT480578 | BZW1 | basic leucine zipper and W2 domains 1 | 2 | 2 | ||||||||
MIRT480915 | BCL2L11 | BCL2 like 11 | 4 | 3 | ||||||||
MIRT481532 | ARL5B | ADP ribosylation factor like GTPase 5B | 2 | 8 | ||||||||
MIRT481681 | ARAP2 | ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 | 2 | 2 | ||||||||
MIRT481724 | APPBP2 | amyloid beta precursor protein binding protein 2 | 2 | 6 | ||||||||
MIRT481938 | ANKRD11 | ankyrin repeat domain 11 | 2 | 12 | ||||||||
MIRT487099 | C2orf44 | WD repeat and coiled coil containing | 2 | 2 | ||||||||
MIRT489294 | RBM8A | RNA binding motif protein 8A | 2 | 8 | ||||||||
MIRT492255 | SLC35F5 | solute carrier family 35 member F5 | 2 | 2 | ||||||||
MIRT493268 | MAP3K4 | mitogen-activated protein kinase kinase kinase 4 | 2 | 2 | ||||||||
MIRT494770 | AP1G1 | adaptor related protein complex 1 gamma 1 subunit | 2 | 2 | ||||||||
MIRT496257 | DNAJC28 | DnaJ heat shock protein family (Hsp40) member C28 | 2 | 2 | ||||||||
MIRT497713 | ZNF645 | zinc finger protein 645 | 2 | 2 | ||||||||
MIRT498027 | ZBTB20 | zinc finger and BTB domain containing 20 | 2 | 2 | ||||||||
MIRT499292 | TSPYL1 | TSPY like 1 | 2 | 2 | ||||||||
MIRT500105 | SLC46A3 | solute carrier family 46 member 3 | 2 | 2 | ||||||||
MIRT501020 | SPATA2 | spermatogenesis associated 2 | 2 | 6 | ||||||||
MIRT501816 | NEURL1B | neuralized E3 ubiquitin protein ligase 1B | 2 | 2 | ||||||||
MIRT502296 | GNG12 | G protein subunit gamma 12 | 2 | 6 | ||||||||
MIRT502493 | FAM122B | family with sequence similarity 122B | 2 | 8 | ||||||||
MIRT503948 | MFSD6 | major facilitator superfamily domain containing 6 | 2 | 6 | ||||||||
MIRT504266 | C1orf147 | chromosome 1 open reading frame 147 | 2 | 4 | ||||||||
MIRT504370 | ARID1B | AT-rich interaction domain 1B | 2 | 6 | ||||||||
MIRT505125 | YOD1 | YOD1 deubiquitinase | 2 | 4 | ||||||||
MIRT506052 | PPP6C | protein phosphatase 6 catalytic subunit | 2 | 4 | ||||||||
MIRT506481 | MYO5A | myosin VA | 2 | 6 | ||||||||
MIRT506967 | HOXA10 | homeobox A10 | 2 | 6 | ||||||||
MIRT507728 | CLIC4 | chloride intracellular channel 4 | 2 | 4 | ||||||||
MIRT513081 | IL20RB | interleukin 20 receptor subunit beta | 2 | 6 | ||||||||
MIRT513570 | FKBP14 | FK506 binding protein 14 | 2 | 2 | ||||||||
MIRT513631 | UBE2A | ubiquitin conjugating enzyme E2 A | 2 | 4 | ||||||||
MIRT513692 | RNF111 | ring finger protein 111 | 2 | 2 | ||||||||
MIRT513764 | PEX5L | peroxisomal biogenesis factor 5 like | 2 | 4 | ||||||||
MIRT520786 | TBX18 | T-box 18 | 2 | 4 | ||||||||
MIRT523402 | GRIK3 | glutamate ionotropic receptor kainate type subunit 3 | 2 | 4 | ||||||||
MIRT525719 | DCAF12L2 | DDB1 and CUL4 associated factor 12 like 2 | 2 | 2 | ||||||||
MIRT527750 | NANOGNB | NANOG neighbor homeobox | 2 | 2 | ||||||||
MIRT532823 | ZNF827 | zinc finger protein 827 | 2 | 2 | ||||||||
MIRT534603 | RORA | RAR related orphan receptor A | 2 | 2 | ||||||||
MIRT535762 | MYCN | MYCN proto-oncogene, bHLH transcription factor | 2 | 2 | ||||||||
MIRT536346 | LEFTY1 | left-right determination factor 1 | 2 | 2 | ||||||||
MIRT543081 | APP | amyloid beta precursor protein | 2 | 2 | ||||||||
MIRT544064 | KIAA1462 | junctional cadherin 5 associated | 2 | 2 | ||||||||
MIRT545424 | SLC39A6 | solute carrier family 39 member 6 | 2 | 2 | ||||||||
MIRT546238 | TNRC18P2 | trinucleotide repeat containing 18 pseudogene 2 | 2 | 4 | ||||||||
MIRT546324 | TGFBR3 | transforming growth factor beta receptor 3 | 2 | 2 | ||||||||
MIRT547361 | NAA30 | N(alpha)-acetyltransferase 30, NatC catalytic subunit | 2 | 2 | ||||||||
MIRT547539 | MAML3 | mastermind like transcriptional coactivator 3 | 2 | 2 | ||||||||
MIRT548062 | GOLGA7 | golgin A7 | 2 | 2 | ||||||||
MIRT549248 | ATXN1L | ataxin 1 like | 2 | 4 | ||||||||
MIRT549250 | ATXN1 | ataxin 1 | 2 | 2 | ||||||||
MIRT549467 | ACSL4 | acyl-CoA synthetase long chain family member 4 | 2 | 2 | ||||||||
MIRT549937 | RPL7L1 | ribosomal protein L7 like 1 | 2 | 4 | ||||||||
MIRT551489 | TMEM192 | transmembrane protein 192 | 2 | 4 | ||||||||
MIRT552564 | ZFP36L2 | ZFP36 ring finger protein like 2 | 2 | 4 | ||||||||
MIRT553688 | TFAP4 | transcription factor AP-4 | 2 | 4 | ||||||||
MIRT553951 | STAMBP | STAM binding protein | 2 | 2 | ||||||||
MIRT554163 | SLC7A2 | solute carrier family 7 member 2 | 2 | 4 | ||||||||
MIRT554477 | SAMD12 | sterile alpha motif domain containing 12 | 2 | 2 | ||||||||
MIRT554918 | RAP2C | RAP2C, member of RAS oncogene family | 2 | 2 | ||||||||
MIRT555003 | RAB39B | RAB39B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT555109 | PURB | purine rich element binding protein B | 2 | 2 | ||||||||
MIRT555445 | NT5C3A | 5'-nucleotidase, cytosolic IIIA | 2 | 2 | ||||||||
MIRT555535 | PLEKHA3 | pleckstrin homology domain containing A3 | 2 | 2 | ||||||||
MIRT556092 | MORC3 | MORC family CW-type zinc finger 3 | 2 | 2 | ||||||||
MIRT556571 | LIFR | LIF receptor alpha | 2 | 2 | ||||||||
MIRT556936 | INO80D | INO80 complex subunit D | 2 | 4 | ||||||||
MIRT558176 | EIF5A2 | eukaryotic translation initiation factor 5A2 | 2 | 2 | ||||||||
MIRT558368 | DIDO1 | death inducer-obliterator 1 | 2 | 4 | ||||||||
MIRT558464 | DCUN1D1 | defective in cullin neddylation 1 domain containing 1 | 2 | 2 | ||||||||
MIRT559236 | BICD2 | BICD cargo adaptor 2 | 2 | 4 | ||||||||
MIRT560099 | ERCC8 | ERCC excision repair 8, CSA ubiquitin ligase complex subunit | 2 | 2 | ||||||||
MIRT560725 | ZNF749 | zinc finger protein 749 | 2 | 2 | ||||||||
MIRT561142 | SPAG1 | sperm associated antigen 1 | 2 | 2 | ||||||||
MIRT561721 | PPP2R2A | protein phosphatase 2 regulatory subunit Balpha | 2 | 2 | ||||||||
MIRT562484 | CHORDC1 | cysteine and histidine rich domain containing 1 | 2 | 2 | ||||||||
MIRT562681 | AGO4 | argonaute 4, RISC catalytic component | 2 | 2 | ||||||||
MIRT564997 | WNK1 | WNK lysine deficient protein kinase 1 | 2 | 2 | ||||||||
MIRT565068 | USP25 | ubiquitin specific peptidase 25 | 2 | 2 | ||||||||
MIRT565184 | TTC37 | tetratricopeptide repeat domain 37 | 2 | 2 | ||||||||
MIRT565946 | RREB1 | ras responsive element binding protein 1 | 2 | 2 | ||||||||
MIRT566315 | POU2F1 | POU class 2 homeobox 1 | 2 | 2 | ||||||||
MIRT566435 | PHF3 | PHD finger protein 3 | 2 | 2 | ||||||||
MIRT566485 | PCCB | propionyl-CoA carboxylase beta subunit | 2 | 2 | ||||||||
MIRT566612 | NR3C1 | nuclear receptor subfamily 3 group C member 1 | 4 | 2 | ||||||||
MIRT566761 | MOB4 | MOB family member 4, phocein | 2 | 2 | ||||||||
MIRT566867 | LRRC1 | leucine rich repeat containing 1 | 2 | 2 | ||||||||
MIRT567232 | HSPE1-MOB4 | HSPE1-MOB4 readthrough | 2 | 2 | ||||||||
MIRT567245 | HSPA13 | heat shock protein family A (Hsp70) member 13 | 2 | 2 | ||||||||
MIRT567292 | HNRNPAB | heterogeneous nuclear ribonucleoprotein A/B | 2 | 2 | ||||||||
MIRT568426 | ATF7IP | activating transcription factor 7 interacting protein | 2 | 2 | ||||||||
MIRT570705 | FAM69A | family with sequence similarity 69 member A | 2 | 2 | ||||||||
MIRT570931 | ZNF284 | zinc finger protein 284 | 2 | 2 | ||||||||
MIRT571631 | SMARCA5 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 | 2 | 2 | ||||||||
MIRT571647 | SIX4 | SIX homeobox 4 | 2 | 2 | ||||||||
MIRT574274 | ZNF350 | zinc finger protein 350 | 2 | 2 | ||||||||
MIRT574304 | CMTM6 | CKLF like MARVEL transmembrane domain containing 6 | 2 | 2 | ||||||||
MIRT574614 | LZIC | leucine zipper and CTNNBIP1 domain containing | 2 | 2 | ||||||||
MIRT574843 | CADM1 | cell adhesion molecule 1 | 2 | 2 | ||||||||
MIRT608128 | TSC22D2 | TSC22 domain family member 2 | 2 | 2 | ||||||||
MIRT648849 | WNT7A | Wnt family member 7A | 2 | 2 | ||||||||
MIRT687559 | MLEC | malectin | 2 | 2 | ||||||||
MIRT696548 | HIST1H3B | histone cluster 1 H3 family member b | 2 | 2 | ||||||||
MIRT697517 | ZBTB7A | zinc finger and BTB domain containing 7A | 2 | 2 | ||||||||
MIRT701146 | PANK1 | pantothenate kinase 1 | 2 | 2 | ||||||||
MIRT704284 | DENND5B | DENN domain containing 5B | 2 | 2 | ||||||||
MIRT704541 | CNEP1R1 | CTD nuclear envelope phosphatase 1 regulatory subunit 1 | 2 | 2 | ||||||||
MIRT707687 | GPR50 | G protein-coupled receptor 50 | 2 | 2 | ||||||||
MIRT707810 | TSPAN6 | tetraspanin 6 | 2 | 2 | ||||||||
MIRT710019 | KCNQ5 | potassium voltage-gated channel subfamily Q member 5 | 2 | 2 | ||||||||
MIRT712705 | TEX9 | testis expressed 9 | 2 | 2 | ||||||||
MIRT731264 | ETS1 | ETS proto-oncogene 1, transcription factor | 1 | 1 | ||||||||
MIRT731606 | SMAD4 | SMAD family member 4 | 1 | 1 | ||||||||
MIRT731688 | MAP3K8 | mitogen-activated protein kinase kinase kinase 8 | 3 | 1 | ||||||||
MIRT731796 | ZEB1 | zinc finger E-box binding homeobox 1 | 3 | 1 | ||||||||
MIRT731798 | ZEB2 | zinc finger E-box binding homeobox 2 | 3 | 1 | ||||||||
MIRT732183 | PTGS2 | prostaglandin-endoperoxide synthase 2 | 3 | 1 | ||||||||
MIRT732711 | ADAM10 | ADAM metallopeptidase domain 10 | 4 | 0 | ||||||||
MIRT732936 | HGF | hepatocyte growth factor | 1 | 0 | ||||||||
MIRT733214 | TLR2 | toll like receptor 2 | 2 | 0 | ||||||||
MIRT734500 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 3 | 0 | ||||||||
MIRT734637 | RPE | ribulose-5-phosphate-3-epimerase | 2 | 0 | ||||||||
MIRT735650 | PIK3R1 | phosphoinositide-3-kinase regulatory subunit 1 | 1 | 0 | ||||||||
MIRT736975 | BCL6 | B-cell CLL/lymphoma 6 | 3 | 0 | ||||||||
MIRT737058 | FBXW7 | F-box and WD repeat domain containing 7 | 3 | 0 | ||||||||
MIRT737435 | CLK3 | CDC like kinase 3 | 2 | 0 | ||||||||
MIRT755765 | FOXO1 | forkhead box O1 | 3 | 1 | ||||||||
MIRT755949 | ONECUT2 | one cut homeobox 2 | 7 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|